Human health is strongly intertwined with the health of the microbiome. A large number of studies have shown that the human ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

In localized non-small cell lung cancer (NSCLC), a tumor's ability to use carbon from glucose to feed the tricarboxylic acid ...

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...

Rezivertinib outperforms gefitinib as first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

Although there was a significant decline in the age-adjusted incidence-based mortality rate from 2006 to 2020, our study did not show a significant improvement in survival outcomes,” the researchers ...

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

Million Private Placement Financing from Existing Investors$2.0 Million Funding Advance from the Cancer Prevention and Research Institute of ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...